Gregory M. Asnis

Albert Einstein College of Medicine — United States

Medicine · Health Sciences

52h-index8.2kcitations173works17.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(41), Stress Responses and Cortisol(37), Tryptophan and brain disorders(35), Bipolar Disorder and Treatment(24), Neurotransmitter Receptor Influence on Behavior(20)

Publications173 total

IFN-Induced Depression: A Role for NSAIDs
Psychopharmacology Bulletin·2025· 49 cited
Immune and neural response to acute social stress in adolescent humans and rodents
Translational Psychiatry·2024· 3 citedOpen Access
Immune and Neural Response to Acute Social Stress in Adolescent Humans and Rodents
2024Open Access
Lurasidone-Induced Urinary Retention
The Primary Care Companion For CNS Disorders·2023
Beyond Serotonin
2023· 1 cited
Pharmacological Treatments for Tinnitus
JAMA·2020· 3 cited
Catatonia Secondary to Hypothyroidism May Be Very Responsive to Electroconvulsive Therapy
Journal of Ect·2020· 3 cited
An Examination of the Relationship Between Insomnia and Tinnitus: A Review and Recommendations
Clinical Medicine Insights Psychiatry·2018· 38 citedOpen Access
A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633)
Expert Opinion on Drug Safety·2016· 5 cited
Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians
International Journal of Molecular Sciences·2015· 99 citedOpen Access
Levomilnacipran for the treatment of major depressive disorder: a review
Neuropsychiatric Disease and Treatment·2015· 40 citedOpen Access
EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]
Neuropsychiatric Disease and Treatment·2014Open Access
EMSAM (deprenyl patch): how a promising antidepressant was underutilized
Neuropsychiatric Disease and Treatment·2014· 22 citedOpen Access
Higher Doses of Levomilnacipran May Benefit Patients with Severe Depression
MD Conference Express·2014
Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder
The Journal of Clinical Psychiatry·2013· 82 citedOpen Access
Treatment of Insomnia in Anxiety Disorders
2012
Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment
The Journal of Clinical Psychiatry·2010· 84 cited
Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder
Journal of Clinical Psychopharmacology·2009· 74 cited
A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine Extended Release Capsules in Adult Outpatients With Panic Disorder
The Journal of Clinical Psychiatry·2009· 49 cited
Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C
Alimentary Pharmacology & Therapeutics·2007· 145 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Scott Wetzler(10), H. M. van Praag(9), Uriel Halbreich(7), Margaret L Kaplan(6), Jill Harkavy‐Friedman(5), René S. Kahn(5), William C. Sanderson(5), Edward J. Sachar(4), Stephen L. Brown(3), Richard De La Garza(3), Rajan Nathan(3), Deborah S. Lipschitz(3), Peter Chorney(3), Frieda S. Halpern(3), Barbara O. Rothbaum(2), René S. Kahn(2), Martin L. Korn(2), Herman M. van Praag(2), Andrew H. Miller(2), Swami Nathan(2)